Home›Trial›NCT05783622
NCT05783622Phase 1RECRUITING

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Study Summary

This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic carcinoma expressing EGFR.

Conditions
Non-Small Cell Lung CancerRenal Cell CarcinomaSquamous Cell Carcinoma of the Head and NeckColorectal CarcinomaSmall Cell Lung CancerPancreatic Ductal AdenocarcinomaTriple-negative Breast Cancer
Interventions / Drugs
JANX008
View on ClinicalTrials.gov ↗
Sponsor
JANX
Janux Therapeutics
Immuno-Oncology
D39/100
Study Details
Enrollment130 participants
Primary Completion—
Lead SponsorJanux Therapeutics
Data Retrieved2026-04-11 04:18:24.248797+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 1 trials primarily test safety and dosing in a small number of participants (typically 20–100). Results do not yet speak to efficacy. FDA approval is typically many years away from this stage.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 130 participants
Sponsor Catalyst Profile

Janux Therapeutics (JANX) is the sponsoring company for this trial. BiotechSign currently grades this company D (39/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

JANX Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.